Bristol-Myers Squibb Compnay

Bristol-Myers Squibb Pharma Company

Dupont Pharmaceuticals Company

The Dupont Merck Pharmaceutical Company

Other

John Matthew Fevig

Mimi Lifen Quan

James Russell Pruitt

Qi Han

Joseph Cacciola

Celia Dominguez

Donald J P Pinto

Charles G Clark

Patrick Y Lam

Dean A Wacker

Robert A Galemmo, Jr

Karen Anita Rossi

Donald J Pinto

Renhua Li

Donald Joseph Phillip Pinto

Taekyu Lee

Ian S Mitchell

Wenting Chen

Jianxin Feng

Albert Jean Robichaud

Saleem Ahmad

Michael J Orwat

Ruth Richmond Wexler

Irina C Jacobson

Patrick Y S Lam

David J Carini

Matthew M Abelman

Charles A Kettner

Eugene Cruz Amparo

Gregory James Pacofsky

Petrus Fredericus Stouten

Renhau Li

Patrick Yuk Sun Lam

William Henry Miller

Lawrence G Hamann

Pratik Devasthale

Amy Han

Patricia C Weber

Wei Wang

Chia-Lin J Wang

Robert M Knabb

Thomas Peter Maduskuie, Jr

Donald Jp Pinto

Padmaja Mantri

Sheng-Lian O Lee

Zixia Feng

Stephen P O'CONNOR

Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n, n, n, n, A, B, D, E, G, Y, Z, Rand Rare defined herein.

[6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists

Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n, n, n, A, B, D, E, G, J, Y, Rand Rare defined herein.

[6,5]&#x2014;bicyclic GPR119 G protein-coupled receptor agonists

[6,5]-bicyclic GPR119 G protein-coupled receptor agonists

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an DPP4 modulated disease or disorder such as, for example, diabetes, by administration of a therapeutically effective dose of a compound according to Formula I. wherein X, Z, A, R, Y, R, n, and b are as defined herein.

7,8-dihydro-1,6-naphthyridin-5(6H)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase IV and methods

The present application provides pyrrolo(oxo)isoquinolines as modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

Pyrrolo(oxo)quinolines as 5HT ligands

The present application describes compounds according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impaired glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I or pharmaceutically acceptable salt forms thereof, wherein A, B, D, E, m, n, R, R, R, R, R, Rand X are described herein.

Pyrrolo(oxo)isoquinolines as 5HT ligands

Compounds are provided having the formula (I) wherein R, X, Y, Z, A and n are as defined herein, which are inhibitors of dipeptidyl peptidase IV and thus are useful in treating diabetes and related diseases.

Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.

Guanidine mimics as factor Xa inhibitors

The present application describes oxygen and sulfur containing heteroaromatics and derivatives thereof of formula I:or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is O or S and D may be C(&#x2550;NH)NH, which are useful as inhibitors of factor Xa.

Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I:or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.

Guanidine mimics factor Xa inhibitors

The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Nitrogen containing heterobicycles as factor Xa inhibitors

Growing community of inventors

Doylestown, PA, United States of America

John Matthew Fevig